why choose us

First received: August 16, 2022

Clinical Trial: Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Metastatic Castration-resistant Prostate Cancer

Study Type: INTERVENTIONAL


Official Title: Immunotherapy Regimen Given After Targeted Local Cryolysis (TLC) for Patients With Advanced/Metastatic Castration-resistant Prostate Cancer (mCRPC) OR Those With Metastatic Prostate Cancer Who Re

Brief Summary: SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.

Read more